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Abstract 
Phelan-McDermid Syndrome (PMS) is a rare genetic condition characterized by deletion 
or mutation of region 22q13.3, which includes the SHANK3 gene. This population is clinically 
defined as having mildly dysmorphic features, epilepsy, neonatal hypotonia, severely impaired or 
absent expressive language, developmental delays, and intellectual impairments. Among these 
characteristics, individuals with PMS notably have autistic-like traits, which include abnormal 
reactivity to sensory stimuli. However, there are few if any EEG studies done on this population 
with regard to sensory processing. Therefore, this study focuses on event-related potential (ERP) 
comparisons between PMS and controls in a standard auditory gating task that measures 
attenuation of neural activity to repetitive auditory responses. There were 52 participants (27 
females), 37 of which have PMS. Specific comparisons of interest include age, gender, and 
genotype between and within the PMS and control groups. Data analysis included a series of 
linear models using a region-specific and a global (whole-head) approach to characterize neural 
activity. The most notable findings between PMS and controls were in genotype, where PMS 
showed worse gating than controls for the P50 ERP. Within PMS, larger deletion sizes were 
associated with increased auditory processing abnormalities, especially in younger individuals, 
suggesting the possibility for developmentally regulated involvement of additional genes in this 
region. Results suggest that PMS exhibit auditory processing abnormalities that show complex 
variation by deletion-size, gender, and age, which may provide valuable insight into clinical 
characterization of sensory and speech behaviors in future studies. 
1 
Chapter 1: Background 
Phelan-McDermid Syndrome 
Phelan-McDermid Syndrome (PMS), also called 22q13.3 Deletion Syndrome, is 
diagnosed in early childhood and is characterized by a dysfunction in the distal portion of 
chromosome 22 with a breakpoint at 22q13.3. This dysfunction can be a result of either a point 
mutation or a widespread deletion of a chromosome that includes SHANK3, a gene that acts as a 
scaffolding protein in the postsynaptic density of excitatory glutamatergic synapses (Sarasua et 
al., 2011). Of all potential genes that may be deleted from chromosome 22 such as ACR and 
RABL2, the haploinsufficiency of SHANK3 is thought to be the primary cause of the neurological 
and phenotypic features of PMS (Phelan & McDermid, 2011). The clinical features of this 
SHANK3 deletion or mutation include autistic traits, mildly dysmorphic features such as a 
bulbous nose, deep-set eyes, long eyelashes, and an elongated skull, epilepsy, neonatal 
hypotonia, severely impaired or absent expressive language, and other developmental delays and 
intellectual deficits (Phelan & McDermid, 2011; Sarasua et al., 2011). Multiple organ systems 
such as cardiac, gastrointestinal, renal, immune, respiratory, and endocrine can also be affected, 
although these characteristics are less defined (Reierson et al., 2017). An estimated 84% of 
individuals with PMS also meet the criteria for Autism Spectrum Disorder (ASD), according to a 
study of 30 patients with PMS. In the same study, 77% of the PMS patients had severe to 
profound intellectual disability, and only five of the participants used words to communicate 
(Soorya et al., 2013). There are several differential diagnoses and comorbidities for PMS that 
make it difficult to know exactly how many individuals are affected by PMS or which symptoms 
are specific to PMS. Common misdiagnoses are ASD, Fragile-X Syndrome, and Cerebral Palsy 
for commonalities in behavior, hypotonia, or subtle dysmorphic features (Phelan & McDermid, 
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2011). In addition, over 30% of individuals with PMS required two or more chromosomal 
studies before a deletion or mutation was detected in the 22q13.3 region that led to their 
diagnosis (Phelan, 2008). Overall, PMS is predicted to occur in approximately 2.5 to 10 births 
per million, although this number may be an underestimate given the hurdles with confirmatory 
diagnosis (Phelan & Phelan-McDermid Foundation, 2017).  
Given its relatively recent discovery and under 2,000 known cases (Phelan-McDermid 
Syndrome Data Network, 2017), little investigation has been done using electroencephalography 
(EEG) on individuals with PMS, especially in the realm of sensory reactivity and the potential 
effects of age, gender, and genotype on PMS development. Therefore, the goal of this paper is to 
use EEG to identify whether there are differences in sensorimotor processing among individuals 
with PMS as compared to healthy controls. Here, we focus specifically on ERP differences in 
auditory processing using a standard auditory gating task. The covariates of interest are age, 
gender (male or female), genotype (mutation, deletion, or control), EEG system (BioSemi, EGI), 
deletion size (kilo-bases), and number of trials.  
Foundational Research 
Auditory gating, and sensory gating in general, is a regulatory mechanism in which 
neural processing of redundant or unnecessary sensory information is attenuated. Gating is 
critical for directing the brain’s resources to relevant environmental stimuli and avoiding sensory 
overload (Davies, Chang, & Gavin, 2009). Gating can be used more generally as a method of 
measuring the strength of inhibitory pathways in the central nervous system (Hetrick Sandman, 
Bunney, Jin, Potkin, & White, 1996). A common measure of gating responses is an event-related 
potential (ERP), which we measure using EEG. An ERP is a scalp recording of electromagnetic 
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activity generated by neurons in accordance with an internal or external event, decision, or 
response (Luck, 2012).  
There are generally three auditory ERP components of interest in basic auditory 
processing: the P50, N1, and P2. The P50 is a fronto-centrally organized positive ERP 
component that generally occurs around 50 milliseconds post-stimulus and represents the brain’s 
initial cortical registration of an auditory event. The P50 is primarily generated by the temporal 
lobe (Huang et al., 2003; Korzyukov, et al., 2006) and is thought to occur as a mechanism by 
which we filter out redundant or trivial information to avoid information overload by attenuating 
the second of two identical auditory stimuli presented in close succession (Sur & Sinha, 2009; 
Yadon, Bugg, Kisley, & Davalos, 2009). The P50 has an additional frontal lobe generator that is 
crucial to the gating response; impairments in gating may stem from abnormalities in this fronto-
temporal interaction (Korzyukov, et al., 2006).  
Following the P50 is the N1, or N100, which is a negative ERP component that generally 
peaks around 90-200 milliseconds after stimulus onset. Its scalp topography is fronto-centrally 
organized in adults but temporally organized in children under 8 years old (Bruneau, Roux, 
Guerin, Barthelemy, & Lelord, 1997). There are 3 subcomponents of the N1 (N1a, N1b, N1c) 
differentiated by their neural generators, which are the primary auditory cortex, auditory 
association cortex, and a diffuse central non-specific system (Budd, Barry, Gordon, Rennie, & 
Michie, 1998). However, the subcomponents are not always distinguishable and often appear to 
be one N1 peak, as it is in this study. Overall, the N1 is associated with detailed processing of 
stimulus properties and in the case of auditory gating, may be further used to detect matches or 
mismatches between consecutive stimuli.  
4 
After the N1 is a centrally organized positive deflection called the P2, or P200 ERP, that 
reaches its peak amplitude around 100-250 milliseconds after stimulus onset (Sur & Sinha, 
2009). The P2 reflects the brain’s process of recruiting more resources from the temporal, 
frontal, and parietal lobes in the case of an auditory stimulus. Two main generators of the P2 
ERP are Heschl’s gyrus and the auditory association cortex among other areas (Crowley & 
Colrain, 2004). At this stage, the brain is registering stimulus quantities and determining if you 
are sensing an identifiable object. The amplitude and latency of all three ERP components—P50, 
N1, P2—differ within individuals and more so for the N1 and P2 than the P50, especially with 
age (Budd et al., 1998; Crowley & Colrain, 2004; Key, Dove, & Maguire, 2005). With a typical 
gating response, the amplitude and latency of the P50, N1, and P2 are significantly reduced after 
a second identical auditory stimulus is presented.  
In clinical populations with sensory hyperreactivity, such as individuals with Fragile-X 
Syndrome, there is generally an increase in amplitude of these ERP components alongside a poor 
gating response, quantified as a reduction in percent attenuation to repeated stimuli, particularly 
in the N1 component (Ethridge et al., 2018). However, PMS is classified by sensory 
hyporeactivity rather than hyperreactivity. In this case, we expect PMS patients to have lower 
amplitude ERPs than healthy controls. From evaluation of preliminary data, we still predict that 
PMS will show a dissociable deficit in the gating response. Rather than having a hyperresponsive 
neural response to the auditory stimuli, PMS may have a hyporesponsive neural response, which 
would still cause poor gating if the hyporesponsivity resulted in similar low amplitude ERPs 
between the first and second stimulus. That is, PMS would have a lower amplitude than the 
healthy controls for the first stimulus and an overly positive or negative amplitude for the second 
stimulus for positive and negative ERP components, respectively. This neurophysiological 
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response would be indicative of poor gating, or a reduced ability to filter out unnecessary sensory 
information. 
Age 
For healthy children under age 8, there can be wide variation in auditory gating. 
Generally, however, children have higher amplitudes and longer latencies of early ERP 
components than their adolescent and adult counterparts (Brinkman & Stauder, 2007; Freedman, 
Adler, & Waldo, 1987). It is not until age 8 that auditory gating responses are reliably observed, 
and adult levels may not be observed until late adolescence (Davies, Chang, & Gavin, 2009). In 
PMS, by age 5, individuals generally show severely attenuated motor and sensory development, 
and discrepancies between performances of children with PMS versus their healthy peers 
become increasingly apparent as both groups age. Therefore, we predict more of a similar pattern 
for PMS and controls before age 5 as compared to over 5, but with PMS children still falling 
below amplitudes and having longer latencies than the controls. Some PMS patients even 
experience sporadic cognitive regression, in which they become worse at cognitive or sensory 
tasks for at least three months. On average, this occurs around age 6 in PMS, which is much later 
than regression seen in other neurodevelopmental disorders, such as ASD (Reierson et al., 2017). 
Since the present study has 17 participants under 8 (96 months), we predict that we will see more 
variable gating responses than we would from an older sample, with ERP abnormalities 
potentially correlating with clinical variables indicating behavioral regression.  
Gender 
PMS is diagnosed in males and females equally, and no known differences exist between 
males and females in the severity of PMS or symptomology. However, there is a pre-existing 
difference in ERP responses to an auditory gating task for healthy individuals. Females generally 
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have higher amplitude ERPs but similar latencies as males (Freedman, Adler, & Waldo, 1987). 
There are a few proposed explanations for this occurrence often revolving around anatomical 
differences. One possibility is that females have thinner skulls than males, which results in 
higher amplitude signals penetrating the bone (Cuffin, 1993; Pfefferbaum, 1990; Pfefferbaum & 
Rosenbloom, 1987). However, one large-scale study found that females have thicker skulls than 
males in the frontal, parietal, and occipital regions, suggesting that skull thickness contributes 
less variation in EEG amplitudes than intracranial differences (Li, Ruan, Xie, Wang, & Liu, 
2007). Hagemann, Hewig, Walter, and Naumann came to the same conclusion in 2008.  
Other possibilities include gender differences in tolerance for loud tones, differences in 
attention or arousal, and hormones, although reproductive hormones and steroids have been 
discounted as major contributors to basic sensory ERP amplitudes (Hetrick et al., 1996). 
According to a study in 2010 that used EEG and NIRS, females also differ from males in resting 
brain activity, even after controlling for hormonal effects and differences in hemoglobin 
concentrations. Therefore, females may simply have differences in functional connectivity than 
males, which result in ERP amplitude differences among the genders (Jausovec & Jausovec, 
2010). The precise mechanism underlying the relationship between ERP amplitudes and gender 
is still unclear at this stage. Despite this, we would expect to see individuals with PMS follow the 
same pattern as the typically developing population, where females have higher ERPs than 
males. Theoretically, then, females with PMS would have higher amplitude ERPs than males 
with PMS, while both genders would have lower gating responses than their healthy counterparts 
would.  
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Genotype  
Several genotype studies have found a positive correlation between deletion size and the 
number and severity of behavioral and clinical features of PMS, including developmental delays 
and absence of speech (De Rubeis et al., 2018; Dhar et al., 2010; Jeffries et al., 2005; Sarasua et 
al., 2011; Wilson et al., 2003). A deletion is either interstitial or terminal, meaning there is a 
break either in a middle or end segment of a chromosome (Griffiths, Miller, Suzuki, et al., 2000). 
For PMS, that break point is in the 22q13.3 region of chromosome 22, which encompasses 
SHANK3. A small deletion that inactivates a single gene like SHANK3 has phenotypic 
consequences similar to a point mutation, whereas larger deletions can be multigenic. Larger 
deletions may include micro-RNA, regulatory elements, and genes like IB2 proximal to 
SHANK3. There is an additive impact of deletions, meaning that larger deletions affect a greater 
range of genes and may ultimately lead to variations in type and severity of phenotypes (Sarasua 
et al., 2011).  
Given this information, we are utilizing deletion sizes gathered from genetic testing to 
determine if there is a pattern between deletion size and auditory gating responses. If so, deletion 
size may be a mediating factor in the relationship between gating responses of individuals with 
deletions versus point mutations. In general, a deletion can affect multiple genes, while a point 
mutation, a change in a single nucleotide base, affects a single gene. Thus, we predict that 
deletions will show more severe deficits characterized by lower ERPs, longer latencies, and less 
effective gating than mutations and that this relationship will be stronger for larger deletions. The 
genetic variation of mutations and deletions as a source of physiological variation may be an 
important factor to consider in future studies of PMS, particularly given the small sample sizes 
likely to be available for studies of this rare disorder.  
8 
Chapter 2: Overview of the Experiment 
Purpose 
 Since little is known about normal patterns of EEG for PMS, and few if any comparative 
analyses of their ERPs exist, our data and methods are the first of their kind for this population. 
Therefore, this study is necessarily exploratory in nature and uses basic, common EEG 
processing techniques to provide a baseline of information for future studies of PMS. 
The overarching goal of this experiment was to look at between and within subject ERP 
amplitude and latency comparisons based on age, gender, and genotype in PMS and controls for 
a standard auditory gating task in order to provide basic characterization of variabilities in PMS 
sensory processing. The outcome of these comparisons, regardless of the findings, will help 
direct future research and therapeutic development for this understudied population. 
Research Objectives 
The goals of the study are to assess whether (1) individuals under age 8 with PMS will 
show similar gating responses to individuals over age 8 with PMS. Do children with PMS hit 
maximal development in sensory processing between 0-8 years old or regress as they get older? 
(2) Do we see differences between PMS and controls with respect to age? (3) PMS is known to 
occur about equally in males and females. Does one gender have more of a developmental delay 
in terms of an auditory gating response? (4) Do we see differences between PMS and controls 
with respect to gender? (5) Does the presence of a SHANK3 gene deletion versus mutation 
determine degree of impairment in terms of an auditory gating response? Is there an effect of 
deletion size on this relationship? (6) Since the PMS population is clinically defined as having 
sensory impairment, will individuals with PMS have weaker gating responses than controls? (7) 
Given the inherent variability in this population, which may also include topographic 
9 
representation of auditory components, do we see similar results for averaging over relevant 
auditory electrodes compared to using a whole-head approach? 
Our research questions, then, are the following: We hypothesize that (1) individuals 8 or 
under with PMS will show higher amplitudes and longer latencies than individuals over 8 with 
PMS but will have similar gating responses due to reduced cortical development in adults. (2) 
Adults with PMS will have attenuated amplitudes and gating and longer latencies compared to 
controls. (3) Females will have a significantly higher ERP amplitude overall, consistent with 
gender effects in typically developing controls, but will not significantly differ in their latencies 
or auditory gating response compared to males, consistent with disorder-related deficits. (4) Both 
males and females with PMS will have lower amplitudes, longer latencies, and worse gating 
responses compared to control males and females, but the PMS and control females will have 
higher amplitude ERPs overall than the PMS and control males. (5) PMS with deletions will 
have more impaired auditory gating responses than mutations, and this relationship will be 
mediated by deletion size. (6) Individuals with PMS will have weaker gating responses than 
controls. (7) Results from the regional analyses averaging over relevant auditory gating 
electrodes will have stronger effects than the global analyses averaging over every electrode.   
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Chapter 3: Method 
Method 
 The participants underwent resting EEG and a standard auditory gating task (see below 
for task description).  
Participants 
 Fifty-five males and females were recruited for this study, however EEG data from three 
of the participants were not salvageable (ages 40, 82, and 95 months, 2 females). The remaining 
52 participants (age range=46-216 months, 27 females) were recruited from Boston Children’s 
Hospital, Icahn School of Medicine at Mount Sinai, Rush University Medical Center, and UT 
Southwestern Medical Center (Table 2). Of the 52, 37 have a diagnosis of PMS. The exclusion 
criteria for these participants included having a primary language other than English or an age 
outside of the range 3-21. Healthy controls were judged by the same criteria, but they were also 
excluded if they had a history of a learning, developmental, psychiatric, or neurological disorder, 
seizures, or current psychotropic medication use.  
Procedures 
 Prior to the EEG tasks, control participants, or for individuals under 18, their parent or 
guardian, filled out a consent form, eligibility sheet, and demographic questionnaire including a 
medication log. Due to intellectual impairment in the PMS group, documentation and consent 
was completed by a parent or guardian. Participants in the PMS group only would then undergo 
genetic testing. Both groups would have either a 33-channel BioSemi, 128-channel BioSemi or 
128-channel EGI brand EEG net set up for resting brain activity measures depending on data 
collection site. Importantly, phantom testing of this task prior to study initiation showed 
comparable data from each system type, given certain pre-processing steps as described below. 
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Regardless, system type was included in all analyses. Resting EEG was recorded for 10 minutes 
while the participant watched a movie of their choice with the sound muted. Afterward, they 
would perform an auditory gating task while EEG was recorded. Individuals would hear a 5ms 
broadband noise burst (75db), with the stimulus onset marking 0ms. Exactly 500ms later, a 
second identical auditory stimulus was presented. Participants were instructed to listen but not 
respond to the sounds. Each participant listened to 150 pairs (S1, S2) of these auditory stimuli 
with an average inter-trial interval of 4,000ms, making the total task duration around 11.25 
minutes.  
Data  
The data is stored in a protected database belonging to the Brain and Biomarker 
Laboratory at the University of Oklahoma. There are 52 individuals in the dataset (37 have been 
diagnosed with PMS, 15 are controls with subjects ranging from age 46 to 216 months), 27 are 
females, and there is no missing data aside from 3 deletion subjects missing deletion size 
information (see Table 2 for demographics by group). Each individual has data consisting of 
their ID, genotype (control, deletion, and mutation), age (in months), gender (male, female), 
amplitudes (μV), and latencies (ms) of responses to stimulus 1 and stimulus 2 for P50, N1, and 
P2. Subjects with deletions have additional information regarding their deletion size as a 
continuous variable (kilo-bases).  
EEG Analysis 
After the EEG data was collected, pre-processing was performed according to previously 
defined guidelines that utilized a combination of BESA 6.1 (MEGIS Software, Grafelfing, 
Germany), EEGlab 14.1.1 (Delorme & Makeig, 2004), and Matlab R2017a (The Mathworks, 
Natick, MA). Data were digitally filtered from 0.5 (12dB/octave slope; zero phase) to 50Hz (24 
12 
dB/octave slope; zero-phase) with a 60Hz notch filter and re-referenced to average reference. 
Bad sensors were interpolated in BESA 6.1 (no more than 5% of total number of sensors). Since 
some participants had EEG data from 33-channel BioSemi nets, all of the data were re-montaged 
to a standard 33-channel montage (Figure 12). We then ran an independent component analysis 
(ICA) using EEGlab 14.1.1 and removed high amplitude components associated with eye 
movement, muscle movement, heart rate, and other noise from the data. Every participant 
retained at least 75% of usable trials with a minimum of 65 trials each (PMS M = 116.1, S.D. = 
30.4; Control M = 116.2, S.D. = 27.8). Afterward, we resampled all of the data to 500Hz and 
averaged each file from 250ms before stimulus 1 to 500ms after stimulus 2 (-250 to 1000ms). 
Before statistical analyses were performed, we looked at the general sample characteristics 
(Table 2), descriptive statistics (Table 3), regional amplitudes (μV) (Figure 3), and global 
amplitudes (μV) (Figure 7) for the PMS and control groups to examine overall response patterns 
in the data. Figures 3 and 7 show a general decrease in amplitude for stimulus 2 as expected with 
a normal gating response. 
Regional Amplitude Analysis 
The primary dependent variables for the region-specific set of ERP analyses were mean 
amplitude (μV) and latency (ms) for the P50, N1, recalculated N1 (as described in the following 
paragraph), and P2 for stimulus 1 and 2. To measure amplitudes and latencies at stimulus 1 and 2 
separately across groups, we defined a time window for each ERP component of interest (P50: 
[40-130 ms; 540-640 ms]; N1: [100-240 ms; 600-740 ms]; P2: [160-300 ms; 650-800 ms]) post-
stimulus 45-75 ms around peak amplitudes from grand averages, with a range dependent on 
variation in individual topographies. Peak amplitude and latencies in the respective time 
13 
windows were calculated as the most positive (P1, P2) or negative (N1) deflection occurring 
within the relevant time windows using Matlab R2017a (The Mathworks, Natick, MA). 
Upon visual examination of the scalp topographies at the peaks of interest, we found 
significant variation between N1 topographies; 22 participants had temporally lateralized N1s, 16 
were fronto-centralized, and 14 were widely distributed or unidentifiable. Topographical 
variations were unsurprising given the age range of our participants and previous literature on 
typically developing brains (Pang & Taylor, 2000). However, we could not average over as 
many electrodes as required to accommodate all of the N1-associated activation with a universal 
set of electrodes. Therefore, we ran two versions of regional analyses for the N1. One version 
averaged the N1 over the same electrodes as the P50 and P2, which included frontal electrodes 
FC5, FC6, F3, FC1, F4, FC2, Fz, and the Cz (Figure 12). The second ‘best electrode’ version 
classified the N1 (henceforth called NN1 for newly calculated N1) according to each individual’s 
most negative non-occipital electrode 100-240ms and 600-740ms after the first and second 
stimulus, respectively.  
After quantifying the ERP component amplitudes and latencies, there were eight 
dependent variables for the regional analysis and too few degrees of freedom to include all 
independent variables, covariates, and interactions as necessary for exploratory analyses. So, we 
first ran the elastic net protocol in SAS 9.4 (SAS Institute, Cary, NC) using proc glmselect to 
determine the best configuration of equations for each dependent variable. Elastic net combines 
ridge regression, where a small bias or shrinkage of highly correlated coefficients is added to 
predictors to alleviate the influence of multicollinearity (Hoerl & Kennard, 1970), and the least 
absolute shrinkage and selection operator (lasso) that minimizes the residual sum of squares such 
that the sum of absolute values of regression coefficients is smaller than a specified constant. 
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This combination includes positive features of the sub-optimal methods like forward selection 
and optimal methods like ridge regression that are difficult to interpret (Tibshirani, 1996). 
The selection criteria included a maximum of 120 steps, where each added variable 
increases the AIC. Using the equations from elastic net, we ran regression models with proc glm 
on P50, N1, recalculated NN1, and P2 mean amplitudes and latencies for both stimuli for the 
PMS and control groups with covariates age, gender, genotype, number of trials, deletion size, 
EEG system, stimulus, and interaction terms chosen by the elastic net selection process. See 
tables 4 through 7 for all equations resulting from model selection.  
Global Amplitude Analysis 
The global averaging method quantifies total amount of scalp activity using the absolute 
value and mean of all electrode amplitudes for each time point. Similar to the problem with 
finding an accurate measure of N1, global averaging bypasses the issue of finding a set of 
electrodes that, when averaged, would encompass all of the participants’ brain activity during the 
auditory gating task. This is a concern, since we have several children under 8 in the study as 
well as a population with a rare genetic disorder that may create additional variation in the spatial 
distribution of their responses. The dependent variables for this analysis included global 
amplitude values (μV) and latencies (ms) at stimulus 1 and 2 for the P50, N1, and P2. This 
global approach did not require a recalculated N1, since we found the mean across every 
electrode. Differences for each component were then measured using the same time windows 
and code as in the previous analyses, except with global instead of regional mean amplitudes.  
To summarize both sets of analyses, we had one region-specific approach with two 
measures of N1 and one global approach to accommodate topographical variation. With both 
techniques, we could determine whether the more commonly employed region-specific approach 
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has failed to capture differences in neural activation during the auditory gating task for any 
participants. With the global analysis completed, we could address the final qualitative 
hypothesis that results from the regional analysis will be more significant than results from the 
global analyses.  
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Chapter 4: Results 
Regional Results: Between PMS and Controls 
Gating. A main effect of stimulus showed that N1 amplitudes were more negative for 
stimulus 1 than 2, as expected from gating, F(1, 1) = 5.34, p = .025. For NN1, there was a 
significant negative interaction of stimulus and gender, where males had shorter latencies than 
females during stimulus 1 and longer latencies than females for stimulus 2, F(1, 1) = 7.42, p = 
.009. In other words, males had longer stimulus 2 latencies, and females had somewhat longer 
and more abnormal stimulus 1 latencies. There was also a significant interaction of stimulus and 
EEG system for P50 and P2 latency. Latencies were longer for EGI systems during stimulus 2 
and similar for both systems at stimulus 1, F(1, 1) = 10.08, p = .002; F(1, 1) = 4.63, p = .035. In 
general, EGI systems increased in latency over time, while BioSemi slightly decreased.  
Of Potential Clinical Interest. P50 latency had a marginally significant main effect of stimulus, 
where stimulus 1 was more positive than stimulus 2 as expected, F(1, 1) = 3.55, p = .065. N1 
latency had a marginal negative interaction of gating and age, where latencies increased across 
stimuli moreso for older individuals than younger, F(1, 1) = 2.82, p = .099.  
Amplitude. A significant main effect of age (range: 97-216 months) indicated that P50 
amplitudes were smaller for older participants across both groups, F(1, 1) = 7.73, p = .008. A 
main effect of genotype shows that controls have more negative N1 and NN1 amplitudes than 
PMS, implying an impaired N1 response in PMS (F(1, 1) = 5.09, p = .023; F(1, 1) = 4.74, p = 
.034). A main effect of system for N1 and NN1 showed that EGI nets measured more negative 
N1 and NN1s than BioSemi caps, F(1, 1) = 6.15, p = .016; F(1, 1) = 4.62, p = .037. P2 had a 
significant main effect of gender, where males generally had more positive and closer to normal 
P2 amplitudes than females, F(1, 1) = 6.80, p = .012. P50 and NN1 had a significant interaction 
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of gender and genotype, F(1, 1) = 5.97, p = .018; F(1, 1) = 8.19, p = .006. For P50, the order of 
amplitude from smallest to largest was PMS females, control females, PMS males, control 
males. Essentially, PMS males had comparable P50s to controls but PMS females had weaker 
P50s than any other group. For the NN1, the same trend applied. Control males had the most 
negative NN1 amplitudes followed by PMS males, control females, and PMS females. P50 also 
had an interaction of age and system; P50 amplitudes decreased with age for BioSemi systems, 
which may be driving the odd main effect of age with P50, F(1, 1) = 4.44, p = .040. There was a 
significant interaction of genotype and trials, where the difference between controls and PMS for 
N1 and NN1 amplitudes was larger when there were more trials, F(1, 1) = 6.71, p = .012; F(1, 1) 
= 4.63, p = .036. In other words, the difference between controls and PMS was smaller with 
fewer trials. N1 and NN1 had a significant interaction of system by trials, where N1 and NN1 
become more negative with more trials for BioSemi but less so for EGI, F(1, 1) = 12.25, p = 
.001; F(1, 1) = 10.02, p = .003.  
Of Potential Clinical Interest. For P50 and NN1 amplitude, there was a marginal main effect of 
gender, where males generally have more positive P50 amplitudes and more negative NN1 
amplitudes than females, which is opposite of expected and signifies a smaller amplitude range 
for females, F(1, 1) = 3.18, p = .081; F(1, 1) = 3.20, p = .080. NN1 had a marginal interaction of 
gender and system, where males had larger amplitudes with BioSemi and females had larger 
amplitudes with EGI, (F(1, 1) = 2.96, p = .092). P2 had a marginally significant positive 
interaction of age and genotype; controls and PMS were similar for P2 amplitudes at the younger 
end of the spectrum and wildly different at the older end (F(1, 1) = 3.93, p = .053). 
Latency. There was an overall significant effect of gender on NN1, in which males had 
longer latencies than females, F(1, 1) = 5.91, p = .018. However, based on averages in Table 3, 
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this does not appear to be true for controls. NN1 also had a significant interaction of age and 
gender, where females did not change much across age but males generally decreased in latency 
(F(1, 1) = 5.27, p = .025).  
Of Potential Clinical Interest. N1 latency had a marginal main effect of genotype such that 
controls had shorter latencies than PMS, F(1, 1) = 3.83, p = .056. P2 had a nearly significant 
main effect of age, such that older individuals had longer latencies than younger individuals, F(1, 
1) = 3.84, p = .054. Lastly, NN1 latency had a marginal interaction of gender and genotype such 
that females were faster for PMS and males were faster for controls, F(1, 1) = 3.59, p = .063.  
Regional Results: Within PMS 
Gating. Within PMS, there were no main effects of gating, but there was an interaction 
of stimulus and system for P50 latency, F(1, 3) = 14.59, p = .0003. EGI latencies were shorter 
than BioSemi at stimulus 1 and larger at stimulus 2. N1 latency had a deletion size by stimulus 
interaction. As deletion size increased, an abnormal pattern emerged with an increase in stimulus 
1 latencies and decrease in stimulus 2 latencies, F(1, 1) = 7.30, p = .010. N1 latency also had a 
significant interaction of stimulus and genotype, where stimulus 2 latencies are longer for 
deletions but shorter for mutations compared to stimulus 1 (F(1, 1) = 7.69, p = .008). Using 
Table 3, deletions have comparable latencies to controls for stimulus 1 but not 2; mutations have 
more normal latencies for stimulus 2 but not 1. NN1 latency had an interaction of stimulus with 
gender, where females had longer latencies at stimulus 1 and shorter latencies at stimulus 2, F(1, 
1) = 5.50, p = .022  
Of Potential Clinical Interest. P50 latency had a marginally significant main effect of gating, 
where stimulus 1 had more positive P50s than stimulus 2, F(1, 1) = 3.86, p = .054. NN1 latency 
had a marginally significant interaction of gating and trials (F(1, 1) = 3.20, p = .078) and gating 
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and system (F(1, 1) = 3.82, p = .055). Stimulus 1 latencies decreased with trials, while stimulus 2 
latencies increased. Additionally, stimulus 1 and 2 latencies were similar for EGI but stimulus 2 
latencies were much larger for BioSemi. 
Amplitude. P50 and both N1 measures had a main effect of genotype, with mutations 
generally having more positive P50s and more negative N1 and NN1s than deletions, F(1, 1) = 
4.81,  p = .032; F(1, 1) = 7.77, p = .007; F(1, 1) = 5.27, p = .025. N1 also had main effects of age 
and trials, where older individuals and those with more trials had more positive N1s (F(1, 1) = 
7.28, p = .009; F(1, 1) = 6.55, p = .013). There was a gender by system and genotype by system 
interaction for P50, F(1, 1) = 8.43, p = .005; F(1, 1) = 6.12, p = .016. For the gender-system 
interaction, EGI had higher amplitudes for males and BioSemi had higher amplitudes for 
females. For genotype by system, EGI and Biosemi measured approximately the same P50 
amplitude for deletions, and EGI measured approximately the same P50 amplitude for mutations 
and deletions. However, BioSemi showed much higher amplitudes for mutations. P50 also had a 
deletion size by gender interaction, where deletion size increases accompany decreases in 
amplitude faster for males than females, (F(1, 1) = 9.63, p = .003). N1 had a number of 
interactions, like age by genotype (F(1, 1) = 12.29, p = .0009), age by system (F(1, 1) = 4.10, p = 
.048), genotype by system (F(1, 1) = 7.61, p = .008), and system by trials (F(1, 1) = 7.86, p = 
.007). Notably, as age increased, N1 amplitudes were more negative for mutations and were 
actually more positive for deletions. For system, older participants had more positive N1 
amplitudes with BioSemi caps and more negative amplitudes for EGI. The opposite was true 
when participants were younger. In trial-related interactions, EGI and BioSemi had the most 
negative amplitudes at 55 and 190 trials, respectively. NN1 did not have the same interactions as 
N1, meaning that the two measures captured different pieces of information about PMS brain 
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activation. NN1 had interactions between deletion size and gender (F(1, 1) = 14.66, p = .0004) 
and gender and system (F(1, 1) = 5.31, p = .025). As deletion size increased, males increased in 
NN1 amplitude faster than females; males with small deletions were more negative than females 
and males with larger deletions were more positive. In other words, males decreased in 
amplitude with deletion size, while females did not change. EGI females and BioSemi males had 
approximately the same amplitude NN1 as one another, and EGI males and BioSemi females 
were similar and lower amplitude as well. P2 had a deletion size by system interaction (F(1, 1) = 
4.41, p = .041) and a gender by genotype interaction (F(1, 1) = 11.71, p = .001). With deletion 
size increases, P2 amplitudes were smaller with EGI and larger with BioSemi. P2 amplitudes for 
deletions stayed relatively consistent between genders, but males with mutations had higher 
amplitude P2s than females with mutations. The high and low values for mutations were also 
more extreme than deletions.  
Of Potential Clinical Interest. P50 had a marginally significant main effect of deletion size and 
system, in which larger deletion sizes and BioSemi systems were both associated with more P50 
amplitude impairment, F(1, 1) = 3.51, p = .066; F(1, 1) = 2.98, p = .089. P2 had a small main 
effect of trials, F(1, 1) = 2.90, p = .094. N1 had marginally significant interactions for age and 
gender, in which females had more positive N1s overall and were less negative with age, F(1, 1) 
= 3.02, p = .088. P2 had a marginal interaction of deletion size and gender with larger amplitudes 
for males with smaller deletions and females with larger deletions (F(1, 1) = 9.63, p = .003). 
Latency. Again, N1 and NN1 have entirely different results. N1 had a main effect of age, 
where older participants had shorter N1 latencies, F(1, 1) = 4.80, p = .033. NN1 had significant 
main effects of gender and trials. For gender, males had longer NN1 latencies than females, F(1, 
1) = 10.14, p = .002. With trials, latencies increased as trials increased due to an outlier with 186 
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trials and a latency of 34 ms, F(1, 1) = 4.16, p = .046. For interactions, N1 had an age by gender, 
age by system, and genotype by trials effect, F(1, 1) = 6.46, p = .014; F(1, 1) = 4.48, p = .040; 
F(1, 1) = 4.98, p = .030. As age increased, males and females had increasingly different N1 
latencies, where males showed much longer latencies than females at younger ages and much 
shorter latencies for older ages. For age by system, EGI latencies decreased and BioSemi 
latencies increased with age. Younger participants with EGI had longer latencies than BioSemi 
but older participants with BioSemi caps had longer latencies than EGI. The PMS age 
distribution for BioSemi and EGI were similarly shaped, although the average and standard 
deviation of ages for those measured with BioSemi were smaller than for EGI (BioSemi M = 
113.9 months, S.D. = 40.0 months; EGI M = 120.6 months, S.D. = 53.6 months). The age 
discrepancy between systems may explain differences in N1 latencies, although it is concerning 
for BioSemi to show increased latencies for older participants. BioSemi (n = 12) also had fewer 
PMS participants than EGI (n = 25), so an individual’s data could bias the BioSemi average 
more than for EGI (Figure 9). With trial increases, N1 latencies increased for mutations but not 
deletions. NN1 had three interactions: gender by genotype (F(1, 1) = 4.07, p = .048), age by 
system (F(1, 1) = 4.21, p = .044), and gender by system F(1, 1) = 6.97, p = .011. In general, male 
mutations had the longest latencies and female mutations had the shortest latencies, including 
latencies of deletions. For interactions involving system, the age by system effects were the same 
as previously identified, where EGI latencies decreased with age, while BioSemi increased. In 
regards to gender, EGI latencies are relatively consistent across genders, while BioSemi had 
much longer latencies for males than females.  
Of Potential Clinical Interest. N1 latency had a small effect of deletion size, where latencies 
increased with deletion size as would be expected, F(1, 1) = 3.48, p = .069. There was also a 
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marginal N1 interaction between deletion size and age, where participants with large deletions 
stayed relatively consistent in latency across ages, but small deletions had smaller latencies for 
older participants (F(1, 1) = 3.94, p = .053).  
  
23 
Global Results: Between PMS and Controls 
Gating. There was a main effect of stimulus on P50 amplitude, where amplitudes 
decreased from stimulus 1 to 2 as expected, F(1, 1) = 12.64, p = .0008. P50 had an interaction of 
stimulus and system; latencies between systems were similar at stimulus 1, but EGI increased 
and BioSemi decreased by stimulus 2, F(1, 1) = 9.26, p = .004.  
Of Potential Clinical Interest. There was a marginally significant interaction between stimulus 
and genotype for N1 latency (F(1, 1) = 3.11, p = .082) and P2 amplitude (F(1, 1) = 3.77, p = 
.058), where controls had longer latencies for stimulus 2 as is normal, while PMS had longer 
latencies for stimulus 1 that were much larger than any latency values for controls. For P2, 
controls had higher amplitudes than PMS at both time points, and the difference between 
controls and PMS was larger at stimulus 1 than 2. 
Amplitude. For P50, there was a main effect of gender such that males had larger 
amplitude P50s than females, F(1, 1) = 4.90, p = .031. N1 also had a main effect of gender, 
where females had lower amplitude N1s than males, F(1, 1) = 4.67, p = .035. N1 and P2 had 
effects of system, where EGI systems had lower N1 and higher P2 amplitudes than BioSemi 
(F(1, 1) = 14.83, p = .0003; F(1, 1) = 13.73, p = .0005). N1 had a main effect of age as well (F(1, 
1) = 6.74, p = .012); P2 had a main effect of genotype, where PMS had smaller amplitude P2s 
than controls, (F(1, 1) = 6.89, p = .012). All three components had a significant interaction of 
gender and genotype (P50: F(1, 1) = 4.40, p = .041); N1: F(1, 1) = 7.44, p = .009; P2: F(1, 1) = 
4.62, p = .037). Males had higher amplitude P50s, N1s, and P2s than females with a more 
exaggerated difference for PMS. N1 had significant interactions of gender-trials, gender-system, 
and system-trials, in which males had more positive N1 amplitudes than females even between 
systems and as trials increased, (F(1, 1) = 4.29, p = .043; F(1, 1) = 4.05, p = .049; F(1, 1) = 
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16.70, p = .0001). P2 amplitude had a significant interaction of genotype-trials and system-trials. 
PMS had weaker amplitudes than controls, especially as trials increased, and EGI had more 
positive P2s than BioSemi when there were fewer trials, F(1, 1) = 6.61, p = .013; F(1, 1) = 16.19, 
p = .0002.  
Of Potential Clinical Interest. P50 had a marginally significant interaction between age and 
gender such that younger males had higher P50 amplitudes than females but older males and 
females had around the same amplitude P50s, F(1, 1) = 3.05, p = .087. N1 had a marginally 
significant interaction between genotype and trials, where controls and PMS were similar in N1 
amplitude for individuals with fewer trials but increasingly different for people with larger 
numbers of trials (F(1, 1) = 3.99, p = .051). P2 had a small interaction between age and system 
such that F(1, 1) = 3.27, p = .077. 
Latency. P50 had a main effect of gender, where males have longer latencies than 
females (F(1, 1) = 10.55, p = .002). P50 also had a significant interaction of gender and trials, 
where males have longer latencies than females and the difference is greater with more trials, 
F(1, 1) = 9.81, p = .003.  
Of Potential Clinical Interest. There is a marginal main effect for P2 gender (F(1, 1) = 3.00, p = 
.088). Males have somewhat shorter P2 latencies than females, and controls have somewhat 
shorter latencies than PMS. P50 also has a marginal interaction between age and genotype, 
where latency increased with age, and PMS had larger latencies across the entire age range (F(1, 
1) = 2.93, p = .093). 
Global Results: Within PMS 
Gating. There were no main effects of stimulus. N1 amplitude had an interaction of 
gating and deletion size, F(1, 1) = 4.10, p = .048. When variations in topography were examined 
25 
using global amplitudes, PMS participants with larger deletion sizes had more negative N1 
amplitudes at stimulus 1 than 2. Smaller deletions corresponded to the opposite of gating, where 
N1 amplitudes were somewhat more negative at stimulus 2 than 1 (Figure 11).  
Of Potential Clinical Interest. For EGI, P50 latencies were larger at stimulus 2 than 1, but 
BioSemi systems had roughly the same latencies at both time points, F(1, 1) = 3.19, p = .079.  
Amplitude. Older participants had lower P50 amplitudes than younger participants, F(1, 
1) = 6.91, p = .011, possibly due to the excessive neuronal connectivity in children. A P50 and 
N1 amplitude deletion size main effect showed that, larger deletion sizes had weaker P50 and 
more negative N1 amplitudes than smaller deletion sizes, F(1, 1) = 8.96, p = .004; F(1, 1) = 
18.47, p < .0001. P50 and P2 had main effects of system, where P50 amplitudes were 
significantly larger and P2 amplitudes significantly smaller for BioSemi than EGI (F(1, 1) = 
6.35, p = .015; F(1, 1) = 5.01, p = .029). N1 had a main effect of trials such that an increase in 
trials led to more negative N1 amplitudes, F(1, 1) = 12.36, p = .0009. All ERP components had a 
deletion size by gender interaction, F(1, 1) = 38.81, p < .0001; F(1, 1) = 15.01, p = .0003; F(1, 1) 
= 10.20, p = .002. Females had larger amplitudes with larger deletions sizes, and males had 
amplitude decreases for all components. P50 had a deletion size by trials interaction, in which 
P50 amplitudes were smaller with more trials and smallest combined with larger deletions, F(1, 
1) = 15.63, p = .0003. P50 had an x-shaped interaction between gender and system, where males 
had higher amplitudes with BioSemi and females had higher amplitudes with EGI, F(1, 1) = 
6.25, p = .015. P50 and P2 had a gender by genotype interaction, F(1, 1) = 5.57, p = .022; F(1, 1) 
= 7.92, p = .007. Deletions did not have a gender difference for P50 or P2 amplitudes, but 
mutations had higher amplitudes for males than females. N1 had an age by genotype interaction 
F(1, 1) = 4.01, p = .050. N1 and P2 also had a genotype by system interaction, where deletions 
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had fairly similar amplitudes with both systems, but mutations had higher global amplitudes with 
BioSemi caps, F(1, 1) = 4.38, p = .041; F(1, 1) = 7.04, p = .010. 
Of Potential Clinical Interest. P50 had two marginal interactions, including genotype by system 
(F(1, 1) = 3.89, p = .054) and genotype by trials (F(1, 1) = 2.87, p = .096). Deletions and 
mutations had about the same amplitude at 100 trials, but more trials corresponded with higher 
amplitudes for mutations and smaller amplitudes for deletions. N1 had one marginal interaction: 
gender by system, F(1, 1) = 3.40, p = .070. 
Latency. P50 had slightly longer latencies for males and older participants, F(1, 1) = 
4.30, p = .043; F(1, 1) = 5.59, p = .022. P50 also had a gender by trials, gender by system, and 
system by trials interaction, F(1, 1) = 7.07, p = .010; F(1, 1) = 7.69, p = .008; F(1, 1) = 5.56, p = 
.022. For gender, male latencies decreased with more trials, and female latencies increased. 
Gender by system showed that males were similar for EGI and BioSemi, but females had shorter 
latencies with BioSemi. For system, EGI had smaller latencies with more trials, whereas 
BioSemi had longer latencies. P2 had a genotype by system interaction, where EGI’s average P2 
latency was similar for deletions and mutations, while BioSemi had significantly larger latencies 
for mutations (F(1, 1) = 4.44, p = .039). This is likely due to the small number of mutations 
recorded with BioSemi versus EGI systems (n = 1 versus n = 5). 
Of Potential Clinical Interest. There were two marginal main effects for P2: genotype and 
system, F(1, 1) = 2.85, p = .096; F(1, 1) = 3.65, p = .060. Latencies were longer for mutations 
and BioSemi systems. An age by genotype interaction for P50 showed that deletions are 
generally similar across ages but older participants with mutations have longer P50 latencies than 
younger participants with mutations, F(1, 1) = 3.58, p = .064. Lastly, there was a gender by 
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system interaction, where males with EGI nets and BioSemi females both had shorter P50 
latencies than EGI females, F(1, 1) = 7.69, p = .008. 
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Chapter 5: Discussion 
There were a variety of differences in age, gender and genotype between and within PMS 
and controls in this study. The most notable differences between PMS and controls related to the 
hypotheses. We expected that (1) children with PMS would have similar gating responses to 
adults with PMS. As hypothesized, there were no significant differences in gating between PMS 
children and adults in the regional analysis, but there were differences amplitude and latency for 
select ERP components. An age by genotype interaction within PMS suggested that older 
deletions had higher N1 amplitudes than younger individuals, but mutations had smaller 
amplitudes at older ages, meaning genotype differences may result in different behavioral 
phenotypes. We predicted that adults would have smaller amplitudes than children, which is 
consistent with the mutation participants but not deletions for the N1. Since the N1 is related to 
pattern and detail recognition in auditory gating, individuals with SHANK3 deletions may be 
worse at identifying sounds in context than mutations. There was a marginal deletion size by age 
interaction that corroborates this possibility; large deletion sizes had consistent latencies across 
ages but smaller deletions had shorter N1 latencies among older participants, as expected for less 
impaired participants. A deletion size by gating interaction for N1 latency also revealed an 
abnormal pattern in which larger deletion sizes were associated with an increase in stimulus 1 
latencies and decrease in stimulus 2 latencies. Deletion size does account for the wide variation 
in speech and language abilities among PMS patients, which may be the consequence of larger 
deletions having additional auditory processing impairments (Sarasua et al., 2011; Sarasua et al., 
2014). 
For the global approach, amplitudes correspond to neural activity across the whole 
cortex. High amplitudes, or high levels of activity, are expected for stimulus 1 but less for 
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stimulus 2; stimulus 2 bursts should be habituated given that they are identical to stimulus 1 
bursts. With this in mind, older PMS participants generally had lower P50 amplitudes—less 
activity—and marginally longer P50 latencies than younger PMS participants, which is the 
opposite of what the regional analysis suggested. The inconsistency could be explained by 
amplitude and latency changes across stimulus points, which are averaged in these findings. If 
older participants have a drastic decrease in amplitude and increase in latency for stimulus 2, 
which indicates better gating, averages over both time points could be lower than for younger 
individuals with potentially weaker gating. However, there were no significant stimulus by age 
interactions for within comparisons, and scatterplots suggest the same trends for both stimuli. 
Furthermore, this explanation does not address discrepancies between the regional and global 
analyses. Rather, it is possible that the global approach is capturing broader impairment that the 
regional analysis does not. 
Even though lower P50 amplitudes for adults were predicted and exemplified by the 
global analysis, low positive amplitudes do not necessarily indicate better processing or 
connectivity. For instance, we also predicted PMS to have lower amplitudes than controls, given 
that impairment—rather than poor functional connectivity—would likely manifest in this way. 
Therefore, it is possible that older PMS participants are more impaired than younger ones due to 
global cognitive regression (Phelan & McDermid, 2011). If sensory processing is less affected 
than other areas of cognition, this may explain why the global analyses demonstrated opposite 
effects to regional analyses within PMS. However, it could also be that PMS adults have stronger 
P50 amplitudes for the regional analysis due to a stronger auditory processing response to the 
stimuli, whereas less global activity may point to more effective auditory processing. One study 
by Brinkman and Stauder found lower amplitude P50s in typically developing children aged 5-7 
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compared to adolescents and adults, so higher amplitudes in adults are not unheard of in a 
typically developing population (2007). 
There were no significant age interactions within the global analyses to help parse the 
unexpected latency finding. Marginal effects suggested that females had a more drastic 
difference between young and old amplitudes than males, but both had smaller amplitudes on 
average in the older participant group as expected. PMS children did have more variation in ERP 
amplitudes and latencies than adults had in the regional analysis but less so for the global 
analysis (see Table 3). Given the age results, it is unclear whether regression with age is typical 
in PMS, since both analyses yielded different results. Neither version of analyses undoubtedly 
points to regression in adults. However, individuals may still have regressed auditory sensory 
processing; an individual’s data could easily be masked by averages.  
(2) Between PMS and controls in the regional analysis, there was an age by gender 
interaction for NN1 latency. In general, females did not change much across age but males 
generally decreased in latency. All other age interactions were only marginally significant. 
Controls and PMS were more similar when younger and quite different when older, with PMS 
being more impaired. For the global approach, there was only one main effect of age—N1 
amplitude—such that older participants had lower global amplitudes and stronger gating than 
younger participants, where age data was limited to people over 8. Although this was opposite of 
what was predicted, the results suggest that younger participants have weaker amplitudes in 
response to the auditory stimuli. This makes sense given previous data on developmental 
trajectories of auditory gating responses (Davies, Chang, & Gavin, 2009). There were no 
significant age-genotype interactions between PMS and controls, so changes in amplitude, 
latency, and gating across ages (over 96 months) were consistent for both groups.  
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In summary, younger individuals generally had lower amplitude ERPs and longer 
latencies than older individuals according to the regional analyses, while the global analyses 
suggested that younger individuals had higher amplitude ERPs, marginally shorter latencies, and 
less gating than older individuals. The global approach may be capturing global immaturity of 
neural networks in children, whereas the regional approach captures localized impairment of 
auditory processing. Impairment here differs from immaturity in that PMS impairment results in 
hyporesponsiveness (Phelan, 2008), while immature neural networks result in poor inhibition of 
neuronal signaling due to poor myelination and an overabundance of synapses (Supekar, Musen, 
Menon, 2009). Thus, the regional approach is better suited for specifically capturing differences 
in auditory processing but should utilize the best electrode approach to accommodate 
topographical variation. 
(3) Despite PMS occurring equally in males and females, we found a few gender 
differences. There were significant main effects of gender for both regional and global analyses 
between PMS and controls. For the regional analysis, males had longer NN1 latencies and larger 
P2, NN1, and marginally P50 amplitudes than females. Within PMS, females also had shorter 
latencies than males for the NN1. The global analyses were similar; males had longer P50 
latencies and larger P50 and N1 global amplitudes than females. Between and within regional 
analyses suggested that females had longer NN1 latencies at stimulus 1 than males and shorter 
latencies at stimulus 2. The difference in latency from stimulus 1 to 2 was larger for females. 
Thus, females generally had lower amplitude ERPs and shorter latencies than males, both of 
which were unexpected but consistent across analyses. We expected that females would have 
higher ERP amplitudes and similar latencies and gating responses compared to males, none of 
which appears to be true. A gender by genotype interaction further distinguished male from 
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female ERPs, where the order of amplitude from largest to smallest for P50 and NN1 was as 
follows: control males, PMS males, control females, PMS females. This evidence suggests that 
females are occasionally lower amplitude than males, even among controls. Deletion sizes also 
appear to have a greater impact on auditory processing for males than females with P50, N1, and 
P2 amplitudes. In the global analysis, all three amplitude components showed females having 
larger global amplitudes with larger deletions sizes, and males having amplitude decreases for all 
components. Again, this may be related to more extreme global impairment in larger deletions 
alongside abnormal auditory processing. A global between analysis gender by genotype 
interaction for all amplitude components showed males with higher amplitudes than females and 
a more exaggerated difference for PMS than controls. There was no difference for deletions with 
respect to gender in P50 or P2 amplitudes but mutations had higher amplitudes for males than 
females. Taken together, it is unclear whether one gender has more of a developmental delay in 
auditory gating, since both appear more impaired than controls. Males appear to have more 
impaired gating responses—especially under age 8, but females have consistently more impaired 
amplitude responses. These may reflect differences in gender impairment, in which males have 
auditory gating deficits more so than females but females have greater global impairment.  
(4) The hypothesis that males and females with PMS had weaker amplitudes, latencies, 
and gating responses than control males and females does not hold. According to the regional 
analysis, males had larger P2 amplitudes than females. Similarly, the order of amplitudes from 
smallest to largest for regional P50 and NN1 was as follows: PMS females, control females, 
PMS males, control males. In other words, males had larger amplitudes in general and PMS 
females had the weakest amplitudes of any group. Because of the PMS males, PMS did not 
always have smaller amplitudes and latencies than controls; gender modified this effect. This 
33 
may be explained by a gating deficit in males, in which averaging of the stimuli resulted in larger 
amplitudes from poor gating of stimulus 2. It was also false that females in both groups had 
higher amplitude ERPs than the males; females with PMS appeared to have the most impaired 
amplitudes.  
(5) The regional analysis within PMS had a main effect of genotype, in which mutations 
had more positive P50s and more negative N1 and NN1 amplitudes than deletions. There was 
also a marginal deletion size by gating effect for N1, where larger deletion sizes were associated 
with longer stimulus 1 latencies and shorter stimulus 2 latencies. Larger deletion sizes had longer 
latencies for stimulus 1 than 2, while deletions as a whole had shorter latencies at stimulus 1. The 
change in latencies from stimulus 1 to 2 was greater for smaller deletions, indicating a greater 
gating effect, and latencies were much higher for stimulus 2 than 1 as expected.  
For the global analysis a gating by deletion size interaction indicated that larger deletion 
sizes had more negative N1 amplitudes than smaller deletions at stimulus 1 and 2, but more so at 
1. Deletions and mutations had similar latencies with smaller trial numbers and grew 
increasingly different as trials increased. In conclusion, the presence of a SHANK3 gene deletion 
versus mutation corresponded to divergent phenotypes of the auditory gating response, and 
phenotypes of deletion participants varied by deletion size. Overall, deletions had longer 
latencies and worse gating than mutations, especially for larger deletions. Mutations often had 
more extreme amplitude values, possibly because deletions were usually more hyporesponsive to 
the auditory stimuli (Figures 4 and 8). 
(6) Regional analyses between PMS and controls had a main effect of genotype, in which 
controls had more negative N1 and NN1s than PMS that implied impairment in PMS auditory 
processing of stimulus properties. In a genotype by trial interaction, as trial numbers increased, 
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N1 and NN1 latencies for both groups decreased but more rapidly for controls. The difference 
between PMS and controls was larger when there were fewer trials, which is consistent with the 
idea that individuals with more neurological impairment also have more behavioral impairment 
that contributes to trial artifact such that trial numbers negatively correlate with impairment.  
The global between analyses had a marginal genotype-gating interaction for N1 latency 
and P2 amplitude. Controls had longer latencies for stimulus 2 as is normal, while PMS had 
longer latencies for stimulus 1 that were much larger than any latency values for controls. For 
P2, the difference in amplitude between PMS and controls was larger at stimulus 1. Both 
analyses had expected findings under the assumption that PMS had worse gating. Global 
analyses also had a significant effect of genotype for P2 amplitude, where PMS had smaller 
amplitudes than controls. In general, PMS did have flatter trajectories than controls across all 
variables. The reduced gating and amplitude and delayed latencies with PMS match well with 
the clinical aspects of PMS that characterize the population by sensory impairment.  
(7) Results from the regional and global analyses were quite different and difficult to 
compare. Given the inherent variability in the PMS population that may include topographical 
variation in the representation of auditory components, we do not see similar results for 
averaging over relevant auditory electrodes compared to using global averaging. Results from 
the regional analyses with averages over relevant auditory processing electrodes did not 
necessarily have stronger effects than the global analyses. The global analyses appeared to have 
a larger number of significant results for P50 amplitude and latency, but regional analyses had 
more significance for other components, especially for amplitudes. The use of one approach 
versus the other should be determined by the variation of topographies in a given dataset. If the 
variations are extreme as in this data, a combined regional and global approach is better than a 
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single approach. However, the optimal method is the best-electrode approach with individualized 
electrode averaging, since it may bypass issues with using global averaging to make inferences 
about any specific type of cognitive processing. 
Summary 
Within PMS, larger deletion sizes were associated with increased auditory processing 
abnormalities, especially in younger individuals, suggesting the possibility for developmentally 
regulated involvement of additional genes in this region. Auditory gating deficits are commonly 
associated with deficits filtering irrelevant sensory information and can lead to difficulty with 
sensory responsiveness and speech development (Davies, Chang, & Gavin, 2009). The results 
suggest that PMS auditory processing abnormalities exhibit complex variation by deletion size, 
gender, and age, which may provide valuable insight into clinical characterization of sensory and 
speech behaviors in PMS.  
The potential implications of the exploratory findings of age, gender, and genotype 
differences between and within PMS and controls are inherently valuable for directing future 
research. For instance, PMS children under age 8 generally had higher global amplitudes and 
longer latencies than PMS adults, and PMS adults had higher regional amplitudes and longer 
latencies than controls, which suggests slower and less efficient auditory processing in PMS. 
Given that auditory processing abnormalities were found in PMS children, early childhood is a 
logical target for sensory development therapies. Researchers have already determined that 
patients with PMS benefit from early intervention programs along with sport and exercise 
therapy to strengthen their muscles and regular, intense therapies for improving communication 
(Phelan, 2008). Auditory gating with amplitude and latency measures may be effective 
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biomarkers for investigating the efficacy of therapies aimed at improving underlying sensory 
processing abnormalities. 
Gender differences were also observed in the current study, making it another important 
variable to consider in the future. Although PMS previously had no known gender differences in 
genotype or phenotype, males and females in the current study had differences in auditory 
processing. Males generally had longer latencies and higher amplitudes than females and were 
more impacted by deletion size for P50 and NN1 amplitude in the regional analysis. The 
amplitude and latency findings within PMS imply more of a gating deficit for males than females 
with PMS, but more overall amplitude impairment in females. However, there were no 
significant gender-gating interactions aside from NN1 latency.  
For genotype differences, PMS had lower ERP amplitudes and abnormal gating as 
predicted, making the two measurements dissociable and perhaps representing different 
mechanisms that could benefit understanding of differences between neurodevelopmental 
disorders with different combinations of these deficits. For instance, there can be different ERP 
profiles in idiopathic autism, a form of ASD of unspecified cause and for which PMS has high 
comorbidity (Betancur & Buxbaum, 2013; Yuhas et al., 2011). This dissociation may indicate 
that poor gating and high or low ERP amplitudes are the result of hyperresponsiveness or 
hyporesponsiveness to sensory stimuli, respectively, and may help distinguish subtypes of 
idiopathic autism in terms of sensory processing.  
Besides the aforementioned suggestions, future research should emphasize a translational 
approach for understanding PMS. Animal models of PMS could help piece together the 
biological pathways and neurophysiological mechanisms underlying PMS, and clinical research 
can assist development of outcome measures to test the efficacy of treatments. Thus far, animal 
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models of PMS have shown that the loss of SHANK3 is accompanied by reduced AMPA and 
NMDA receptors, destabilized postsynaptic density receptors, and impaired synaptic 
transmission contributing to the hyporesponsiveness in PMS (Costales and Kolevzon, 2015; 
Harony-Nicolas, De Rubeis, Kolevzon, & Buxbaun, 2015). In addition, the exonic region of 
mutation within the SHANK3 gene alters phenotypic effects in mice, which may explain 
differences in human phenotype beyond deletion size (Copping et al., 2017). However, it is 
important to note that SHANK3 mice are point mutations or point deletions that do not 
necessarily correspond to more extensive deletions (Yang et al., 2012). Mouse models of 
deletion size would be a logical step for phenotypical investigation as long as there is accurate 
correspondence between proximal genes deleted in humans and mice. Another beneficial model 
would combine age, gender, and genotype effects between and within wildtype mice and a 
murine line mimicking SHANK3 haploinsufficiency that would inform research on the 
mechanisms driving the interaction and phenotypic effects seen in this study (Harony-Nicolas, 
De Rubeis, Kolevzon, & Buxbaum, 2015).  
 
Concerns 
Instances where one version of analyses implied P50 or P2 amplitudes decreases or N1 or 
NN1 amplitude increases and other versions implied the opposite were unexpected. One of three 
things could cause opposite trends. One unlikely possibility is that outliers may have skewed the 
data in one or more analyses such as the outlier for the regional main effect of trials on NN1 
latency within PMS. Second, the relationship differences could be real and with unclear causes—
potentially due to variability among the younger participants, less efficient neural networks, or 
differences in global versus regional processing. Third, the trend may be the product of 
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collapsing across both stimuli, where high P50 and P2 and low N1 and NN1 amplitudes 
correspond with more effective auditory processing at stimulus 1 and low P50 and P2 and high 
N1 and NN1 amplitudes generally correspond with better gating at stimulus 2. With 
hyporesponsiveness for instance, stimulus 1 ERPs are lower amplitude than expected but remain 
relatively unchanged for stimulus 2. Compared to typical gating, stimulus 1 would be abnormally 
low amplitude and stimulus 2 would be abnormally high. Averaged out and collapsed across 
stimuli, both scenarios might have similar amplitudes, effectively covering up the unusual 
pattern of gating in the hyporesponsive group. 
System effects were another concern. It is unclear why the BioSemi caps and EGI nets 
had opposite effects in certain interactions, such as for P50 and P2, where regional analyses 
suggested that EGI systems increased in latency over time, while BioSemi slightly decreased. It 
is unusual for one system to lead to different conclusions than the other. The effects may not be 
entirely due to the system but rather site effects. Twice as many subjects were recorded using 
EGI systems than BioSemi. EGI also had twice as many males, females, controls, deletions, and 
mutations as BioSemi, which could account for the statistical differences between the systems 
(Table 2). Future research should opt for a single system to minimize the possibility of data 
discrepancies due to system effects. If multiple systems must be used, they should be matched 
across important variables. The sites in this study also used different software. EGI sites used E-
Prime, while BioSemi used Presentation. E-Prime may have created onset delays for the EGI 
systems that influenced latency values. 
 Lastly, instead of having dependent variables for each ERP component across both 
stimuli, it may be beneficial to separate each component into two variables—one for stimulus 1 
and another for stimulus 2. This would eliminate problems associated with interpretation of 
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findings collapsed across the two stimuli. However, doing so would double the number of 
dependent variables used in the present study and would require additional gating variables. This 
was the original approach for this data, but the results were unnecessarily complex. The results 
here help narrow down which variables to consider and whether all three ERP components 
would be useful to include in future studies. Age, for instance, should undergo careful 
consideration during data collection. Unless distinct age groups are desired, researchers should 
be mindful of developmental effects on ERP topographies and select an appropriate age range—
either under or over 8 years old (Bruneau et al., 1997). Gender and genotype differences in PMS 
may also have important consequences for phenotypical characteristics of PMS and should either 
be controlled for or selected for in sampling and analysis. As for ERP components, all three 
contributed significant results; however, studies of children may elect to discard the N1 from 
analyses given its unreliable topography and maturational variability. The N2, or N200, is an 
additional ERP component to consider. Although this component was not included in the present 
study, it has been used in previous auditory gating studies with Fragile-X Syndrome (Ethridge, 
White, Mosconi, Wang, Byerly, & Sweeney, 2016). The N2 is associated with stimulus 
identification, maintaining auditory memory traces, attentional shifts, and novelty detection 
(Patel & Azzam, 2005), which upon visual inspection of Figures 1-8, may also be affected in 
Phelan-McDermid Syndrome. 
  
Limitations and Assumptions 
 There are several major limitations in this experiment mostly involving small sample 
sizes. For instance, the data contains five times more deletions than mutations (30 vs. 6), 
meaning that genotype comparisons had low statistical power. However, since PMS is a rare 
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genetic condition, it can be difficult to acquire a large patient sample. This is especially difficult 
when further subdividing the patient sample, as we did with comparisons between age, gender, 
and deletions versus mutations. Yet, this is the largest sample of PMS patients ever collected for 
an EEG study. If we collected more PMS participants, it would have been unlikely that they had 
a SHANK3 mutation. Therefore, this particular comparison of deletions and mutations was 
exploratory in nature and should be used purely as a guide for future targeted studies aimed at 
recruiting PMS patients with specific genotypes. 
Another sample size issue was in the analyses between PMS and controls, where we 
limited PMS and control comparisons to participants over age 8. There were two main reasons 
for this restriction. One, there was only one control under 8, and two, participants under 8 (17 
PMS) had more topographical variation than adults. With the age restriction in the between-
group analyses, we had a sample of 20 PMS participants versus 15 controls. Regardless, there is 
less cause for concern about exclusions of individuals under 8 in the case-control comparisons, 
since the auditory gating task has a large literature characterizing typical developmental effects 
during this age range (Brinkman & Stauder, 2007; Freedman, Adler, & Waldo, 1987). Our 
within PMS age comparisons of individuals under and over 8 may provide productive 
exploratory findings when compared to literature-based norms.  
Future studies would clearly benefit from larger sample sizes. With a sample size of at 
least 5% of the population, around 100 for PMS, finite population correction would be an option. 
This correction reduces the required sample size for a small population and adjusts variance and 
mean estimates to account only for the proportion of the population absent from the sample 
(Israel, 1992; Lavrakas, 2008).  
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Appendix A: Timetable 
 
Table 1. Experiment Design 
Tasks 
Method of 
Acquisition 
Approximate Length of 
Time 
Informed Consent Computer 2 minutes 
Eligibility Sheet Computer 2 minutes 
Demographic Questionnaire Computer 2 minutes 
Genetic testing – PMS only Researcher 15 minutes 
Medication log – PMS only Researcher 2 minutes 
EEG Application Researcher 10 minutes 
Resting Task Computer 10 minutes 
Gating Task Computer 15 minutes 
Remove EEG Net Researcher 2 minutes 
 Total Time ~60 minutes 
Note: All tasks were performed in one of four facilities: Boston Children’s Hospital, Icahn 
School of Medicine at Mount Sinai, Rush University Medical Center, or UT Southwestern 
Medical Center.  
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Appendix B: Sample Characteristics and Descriptive Statistics 
 
Table 2. Sample Characteristics 
 Age (months) Gender Genotype System 
0-8 8+ Male Female Control Deletions Mutations EGI BioSemi 
Age (mos.) 17 people 35 people 122(47) 122(42) 130(26) 119(52) 114(41) 124(48) 117(36) 
Male 77(15) 147(40)   8 people 13 people 4 people 17 people 8 people 
Female 80(17) 139(37)   7 people 18 people 2 people 18 people 9 people 
Control none 130(26) 8 people 7 people    10 people 5 people 
Deletions 78(16) 158(42) 13 people 18 people    20 people 11 people 
Mutations 83(16) 130(42) 4 people 2 people    5 people 1 person 
EGI 79(17) 134(42) 17 people 18 people 10 people 20 people 5 people   
BioSemi 77(13) 147(29) 8 people 9 people 5 people 11 people 1 person   
Trials 104(35) 
trials 
122(25) 
trials 
117(32) 
trials 
116(28) 
trials 
116(28) 
trials 
117(30) 
trials 
110(34) 
trials 
110(27) 
trials 
129(30) 
trials 
Total 17 people 35 people 25 people 27 people 15 people 31 people 6 people 35 people 17 people 
Note: Numbers in parentheses are standard deviations, and numbers without units represent age in months. 
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Table 3. Descriptive Statistics 
Group Component AmplitudeR1 LatencyR1 AmplitudeR2 LatencyR2 AmplitudeG1 LatencyG1 AmplitudeG2 LatencyG2 
CON P50 2.081 19.27 1.341 26.47 1.923 22.80 1.217 27.80 
 N1 -1.581 33.60 -0.992 40.87 0.537 34.13 0.362 39.87 
 NN1 -3.846 6.333 -2.327 7.867     
 P2 1.744 22.27 1.029 19.27 1.746 25.20 1.159 36.33 
PMS P50 1.656 23.43 1.370 32.19 1.505 24.68 1.218 31.38 
 N1 -1.037 39.73 -0.830 53.38 0.490 44.59 0.397 36.11 
 NN1 -3.155 4.081 -2.616 5.703     
 P2 1.095 24.78 0.817 30.22 1.240 24.62 1.116 40.43 
CONmale P50 2.330 13.88 1.558 24.50 2.158 23.75 1.302 26.63 
 N1 -1.647 32.75 -1.036 30.75 0.560 43.50 0.337 39.38 
 NN1 -4.250 3.625 -2.392 8.500     
 P2 2.037 21.13 1.288 17.75 1.795 9.875 1.188 32.50 
CONfem P50 1.800 25.43 1.094 28.71 1.653 21.71 1.120 29.14 
 N1 -1.504 34.57 -0.941 52.43 0.512 23.43 0.391 40.43 
 NN1 -3.383 9.429 -2.253 7.143     
 P2 1.409 23.57 0.733 21.00 1.690 42.71 1.126 40.71 
PMSmale P50 1.763 23.00 1.410 33.53 1.591 25.47 1.178 32.82 
 N1 -1.043 39.29 -0.942 53.94 0.537 43.71 0.404 42.59 
 NN1 -3.422 3.882 -2.739 8.353     
 P2 1.337 24.41 0.939 29.47 1.338 25.94 1.124 39.06 
PMSfem P50 1.565 23.80 1.340 31.05 1.431 24.00 1.252 30.15 
 N1 -1.032 40.10 -0.736 52.90 0.450 45.35 0.391 30.60 
 NN1 -2.928 4.250 -2.511 3.450     
 P2 0.890 25.10 0.714 30.85 1.158 23.50 1.110 41.60 
Deletions P50 1.522 23.55 1.360 31.06 1.437 24.16 1.223 30.52 
 N1 -0.975 37.81 -0.864 55.77 0.482 43.48 0.401 37.90 
 NN1 -3.066 3.774 -2.645 5.581     
 P2 0.987 27.23 0.771 29.19 1.171 23.10 1.118 40.90 
Mutations P50 2.349 22.83 1.410 38.00 1.856 27.33 1.193 35.83 
 N1 -1.357 49.67 -0.657 41.00 0.531 50.33 0.374 26.83 
 NN1 -3.613 5.67 -2.466 6.333     
 P2 1.651 12.17 1.050 35.50 1.598 32.5 1.107 38.00 
PMSchild P50 1.541 24.76 1.270 34.18 1.579 23.53 1.298 30.59 
 N1 -0.907 40.71 -0.935 57.06 0.575 39.18 0.493 37.00 
 NN1 -3.314 4.294 -2.891 5.882     
 P2 1.034 30.41 0.865 36.47 1.314 28.59 1.307 35.88 
PMSadult P50 1.753 22.30 1.453 30.50 1.442 25.65 1.150 32.05 
 N1 -1.147 38.90 -0.741 50.25 0.417 49.20 0.315 35.35 
 NN1 -3.020 3.900 -2.381 5.550     
 P2 1.147 20.00 0.776 24.90 1.178 21.25 0.954 44.30 
Note: Table values are means. Amplitudes are measured in μV, and latencies in ms.
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Appendix C: Regional Analysis Results 
Table 4. Regional Results: Between PMS and CON 
Group P50A (μV) P50L (ms) N1A (μV) N1L (ms) NN1A (μV) NN1L (ms) P2A (μV) P2L (ms) 
Stim 1 .162(1.29) 6.27(5.21)~ -.038(.317)* 26.7(22.3) .164(1.80) 2.05(1.98) -.652(.894) 13.7(8.70 
Age -.019(.010)** -.057(.111) .001(.008) -.558(.642) .002(.012) -.014(.164) .006(.024) .144(.073)~ 
Gender 0 3.63(1.99)~ 16.2(13.0) .465(1.52) 34.2(25.3) -3.67(2.18)~ 23.2(7.13)* .378(.485)*  
Genotype 0 .621(2.81) 5.26(15.9) 4.84(2.20)* 2.82(13.8)~ 4.32(2.50)* 15.3(10.0) -1.91(1.24)  
System 0 -.715(3.24) -.021(15.9) -5.75(2.48)* 31.8(35.7) -6.97(4.43)* -.838(2.36) .751(.391) 4.79(7.70) 
Trials .008(.014) .039(.106) -.015(.010) -.992(.822) -.009(.014) -.032(.212) .006(.029)  
Stim*Age 1    -.247(.147)~ .004(.007)  .007(.006)  
Stim*Gender 10 -.047(.434) -5.39(5.29)   -.517(.476) -7.99(2.93)** .161(.393)  
Stim*Genotype 10 .468(.444)  -.175(.336)  -.822(.498)  .419(.402)  
Stim*System 10 -.164(.461) -17.6(5.55)** -.566(.350)  -.505(.517)  -.167(.422) -23.1(10.7)* 
Stim*Trials 1 .002(.009)    -.007(.010)    
Age*Gender 0 -.012(.008) -.109(.079) -.008(.006) -.232(.158) .006(.007) -.099(.043)*   
Age*Genotype 0 -.006(.010)  -.004(.008)    .015(.008)~  
Age*System 0 .022(.011)* .102(.110) -.0005(.008)  -<.0001(.011)    
Age*Trials    .005(.005)  .0001(.001) -.0001(.0002)  
Gender*Genotype 00 -1.24(.508)* -5.00(5.74) .298(.397) -11.2(11.9) 1.57(.547)** -6.15(3.23)~ .406(.435)  
Gender*System 00 .651(.529)   -10.8(13.9) -.999(.581)~  -.006(.512)  
Gender*Trials 0 -.012(.012)  .001(.010)      
Genotype*System 00   -.675(.526) -21.4(14.5) .319(.762) 1.30(3.85) -.640(.533)  
Genotype*Trials 0 .008(.016) -.057(.129) -.032(.012)*  -.037(.017)* -.108(.071)   
System*Trials 0 -.021(.018)  .049(.014)** -.283(.274) .060(.019)**    
Model p-value .002 .004 .011 .002 <.0001 .008 .007 .069 
Mean 1.65 24.9 -1.09 41.4 -2.87 5.74 1.14 21.7 
R2 .509 .374 .414 .412 .620 .353 .410 .124 
Note: Table of estimates with standard error in parentheses. ~p < .10, *p < .05, **p < .01, ***p < .001 of the overall effect. Simple 
effects p<.01 are bolded. Only significant variables chosen by elastic net are presented. A non-significant model means the IVs do not 
improve model fit; the model has better fit with just the intercept. 
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Table 5. Regional Results: Within PMS 
Group P50A (μV) P50L (ms) N1A (μV) N1L (ms) NN1A (μV) NN1L (ms) P2A (μV) P2L (ms) 
DeletionSize  -.0001(.0001)~ .0009(.0008) <.0001(<.0001) -.011(.113)~ -.0005(.0003)  <.0001(<.0001)  
Stim 1 .532(.600) 4.92(4.35)~ -.385(.558) -11.5(24.8) .483(1.27) 7.18(6.48) .216(.560)  
Age  .027(.082) -.009(.007)** 1.16(.366)* -.003(.013) .043(.033) -.002(.004)  
Gender 0 -.694(.373)  -.404(7.68) 26.6(32.0) .081(1.23) 18.7(4.81)** .699(.813)  
Genotype 0 -1.31(.691)* 5.16(10.4) -1.42(.793)** -58.9(45.6) -4.40(2.26)* 3.16(3.20) 1.38(1.33)  
System 0 -2.40(.714)~ 13.2(3.77) .567(1.10) 6.70(28.1) 2.27(1.21) 9.37(5.40) -.380(.833)  
Trials   -.006(.005)* -.292(.4350 -.002(.018) .101(.037)* -.007(.009)~  
DS*Age  <.0001(<.0001)  <.0001(<.0001) .0001(<.0001))~     
DS*Gender 0 -.0003(.0001)**   -<.0001(.003) .0005(.0001)***  -.0002(<.0001)~  
DS*System 0    .003(.003) .0001(.0001)  -.0002(<.0001)*  
DS*Trials      <.0001(<.0001)    
DS*Stim 1  -.0004(.001)  .005(.002)**   .0001(<.0001)  
Stim*Age 1   -.003(.003) -.081(.098)   .004(.003)  
Stim*Gender 10   .291(.291) -7.42(9.51)  -6.62(2.82)* .227(.292)  
Stim*Genotype 10 -.692(.537)  .651(.391) -26.7(12.8)* .719(.678)  -.392(.392)  
Stim*System 10 .494(.423) -20.2(5.30)*** -.146(.308) 14.9(10.3) -.464(.543) 5.98(3.06)~ -.249(.309)  
Stim*Trials 1    .199(.164) -.011(.008) -.084(.047)~   
Age*Gender 0   -.006(.003)~ -.268(.105)* -.007(.005)    
Age*Genotype 0  -.066(.086) .018(.005)*** -.452(.238)~ .013(.012)    
Age*System 0   -.009(.004)* -.307(.145)*  -.082(.040)* .001(.004)  
Age*Trials    -.004(.002)     
Gender*Genotype 00    16.9(19.4) 1.40(1.04) -8.36(4.14)* -1.79(.524)**  
Gender*System 00 1.30(.448)**  -.209(.334) 2.83(12.3) -1.35(.588)* -8.47(3.21)*   
Gender*Trials 0   .009(.006) -.087(.190)   .009(.006)  
Genotype*System 00 1.75(.708)*  -1.46(.531)** 30.2(24.1) -1.47(1.23)  .662(.708)  
Genotype*Trials 0    .815(.365)* .024(.019)  -.009(.008)  
System*Trials 0   .018(.006)**      
Model p-value .005 .0002 .0009 .011 .0002 .006 <.0001 <.0001 
Mean 1.51 27.8 -.934 46.6 -2.89 4.89 .956 27.5 
R2 .275 .318 .479 .455 .479 .345 .507 .000 
Note: Table of estimates with standard error in parentheses. ~p < .10, *p < .05, **p < .01, ***p < .001 of the overall effect. Simple 
effects p<.01 are bolded. Only significant variables chosen by elastic net are presented. A non-significant model means the IVs do not 
improve model fit; the model has better fit with just the intercept. A separate model was used for deletion size and deletion size 
interactions. 
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Appendix D: Global Analysis Results 
Table 6. Global Results: Between PMS and CON 
Group P50A (μV) P50L (ms) N1A (μV) N1L (ms) P2A (μV) P2L (ms) 
Stim 1 .127(.273)*** 10.3(11.6) -.062(.169) 13.9(7.27) -.272(.742) -13.7(29.5) 
Age -.009(.006) .325(.392) -.001(.0008)*  .006(.005)  
Gender 0 1.51(.714)* 63.1(20.5)** .532(.286)*  1.13(.910) -5.04(8.29)~ 
Genotype 0 -2.03(1.36) 17.6(15.8) -.159(.447) 4.52(7.85) -2.90(1.19)*  
System 0 .369(1.90) 32.6(38.0) 1.34(.335)***  5.32(1.45)***  
Trials .004(.007) .592(.442) .004(.002)  .011(.006) -.104(.168) 
Stim*Age 1  -.044(.074) .0007(.001)  .003(.003)  
Stim*Gender 10 .242(.263) 2.26(5.26) .113(.077)  .055(.204) -10.3(11.7) 
Stim*Genotype 10 .380(.264) .368(5.52) .076(.081) -19.6(11.1)~ .425(.219)~  
Stim*System 10 .104(.273) -16.7(5.50)**   -.023(.217)  
Stim*Trials 1     .0005(.004) .003(.237) 
Age*Gender 0 -.008(.004)~    -.003(.003)  
Age*Genotype 0 .006(.005) -.179(.105)~ -.002(.001)  .005(.004)  
Age*System 0 .010(.006) .088(.138)   -.009(.005)~  
Age*Trials   -.003(.003)     
Gender*Genotype 00 -.638(.304)* -5.97(6.01) -.235(.086)**  -.511(.237)*  
Gender*System 00 .167(.317) -1.27(6.65) .185(.092)*  .212(.242)  
Gender*Trials 0  -.463(.148)** -.004(.002)*  -.003(.006)  
Genotype*System 00 -.006(.381) 4.52(7.10) -.181(.118)  .122(.313)  
Genotype*Trials 0 .011(.009)  .005(.003)~  .019(.007)*  
System*Trials 0 -.015(.011) -.239(.180 -.011(.003)***  -.033(.008)***  
Model Significance .0003 .002 <.0001 .183 <.0001 .021 
Mean 1.41 27.3 .402 40.0 1.23 31.9 
R2 .528 .506 .567 .070 .603 .184 
Note: Table of estimates with standard error in parentheses. ~ p < .10, *p < .05, **p < .01, ***p < .001. The p-value represents overall 
effects rather than simple effects. Only significant variables chosen by elastic net model selection are presented. Values are bold if 
there is a significant (p < .10) simple effect. Any unlisted estimates of variable levels are reference levels (e.g. Stim 2 is a reference 
level). 
 
 
 
 
54 
Table 7. Global Results: Within PMS 
Group P50A (μV) P50L (ms) N1A (μV) N1L (ms)  P2A (μV) P2L (ms) 
DeletionSize  .0006(.0001)**  <.0001(<.0001)***  <.0001(<.0001)  
Stim 1 .218(.621) 7.08(13.5) -.012(.181) 14.8(7.40) .080(.350) 9.19(24.1) 
Age -.018(.007)* .188(.145)* .001(.002)  -.002(.005)  
Gender 0 -.189(.801) 43.1(18.5)* .012(.215) 12.0(7.72) .473(.632)  
Genotype 0 .547(1.14) 19.2(16.3) .251(.252)  .844(.910) -30.9(18.9)~ 
System 0 -2.34(.702)* 37.9(24.4) -.516(.206)  -1.30(.468)* -39.4(18.6)~ 
Trials .009(.010) .270(.117) -.003(.001)***  -.003(.008) .002(.131) 
DS*Age      -<.0001(<.0001)  
DS*Gender 0 -.0003(.0001)***  -<.0001(.0001)***  -.0002(<.0001)**  
DS*System 0 -<.0001(<.0001)      
DS*Trials  -<.0001(<.0001)***      
DS*Stim 1 -<.0001(<.0001)  -<.0001(.0001)*    
Stim*Age 1   .0005(.001)  .003(.002)  
Stim*Gender 10 .154(.243)  .054(.094) -13.6(10.9) .122(.193)  
Stim*Genotype 10 -.383(.328)  -.050(.127)  -.423(.262) -11.4(14.8) 
Stim*System 10 .208(.262) -11.5(6.42)~ .090(.100)    
Stim*Trials 1 .002(.004) -.052(.100)    -.133(.181) 
Age*Gender 0 .004(.003) .092(.070) .0004(.001)    
Age*Genotype 0 .009(.006) -.213(.112)~ -.003(.002)*  -.003(.005)  
Age*System 0 .006(.004) .054(.089)     
Age*Trials       
Gender*Genotype 00 -1.17(.498)*  -.206(.174)  -1.12(.397)**  
Gender*System 00 .713(.285)* -19.7(7.11)** .200(.109)~  .206(.227)  
Gender*Trials 0 .003(.005) -.312(.117)*   .004(.004)  
Genotype*System 00 1.20(.610)~  .441(.211)*  1.29(.488)* 41.0(19.4)* 
Genotype*Trials 0 -.016(.009)~    -.007(.007)  
System*Trials 0  -.310(.131)*     
Model Significance .004 .013 .0002 .190 <.0001 .058 
Mean 1.36 28.0 .443 40.4 1.18 32.5 
R2 .455 .388 .480 .065 .525 .181 
Note: Table of estimates with standard error in parentheses. ~p < .10, *p < .05, **p < .01, ***p < .001 of the overall effect. Simple 
effects p<.01 are bolded. Only significant variables chosen by elastic net are presented. A non-significant model means the IVs do not 
improve model fit; the model has better fit with just the intercept. A separate model was used for deletion size and deletion size 
interactions. 
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Appendix E: Regional ERP Analyses 
 
 
Figure 1. Regional ERP Analysis of Age (PMS vs. Controls). PMSC = PMS children (n = 17), 
PMSA = PMS adults (n = 20), CONA = Control adults (n = 15). 
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Figure 2. Regional ERP Analysis of Gender (PMS vs. Controls). PMSF = PMS female (n = 20), 
PMSM = PMS male (n = 17), CONF = control female (n = 7), CONM = control male (n = 8). 
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Figure 3. Regional ERP Analysis of Genotype (PMS vs. Controls). CON = control (n = 15), 
PMS = mutations and deletions (n = 37). 
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Figure 4. Regional ERP Analysis of Genotype (PMS Mutations vs. Deletions). PMSD = 
deletions (n = 31), PMSMu = mutations (n = 6). 
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Appendix F: Global ERP Analyses 
 
 
Figure 5. Global ERP Analysis of Age (PMS vs. Controls). PMSC = PMS children (n = 17), 
PMSA = PMS adults (n = 20), CONA = Control adults (n = 15).  
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Figure 6. Global ERP Analysis of Gender (PMS vs. Controls). PMSF = PMS female (n = 20), 
PMSM = PMS male (n = 17), CONF = control female (n = 7), CONM = control male (n = 8). 
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Figure 7. Global ERP Analysis of Genotype (PMS vs. Controls). CON = control (n = 15), PMS 
= mutations and deletions (n = 37). 
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Figure 8. Global ERP Analysis of Genotype (PMS Mutations vs. Deletions). PMSD = deletions 
(n = 31), PMSMu = mutations (n = 6). 
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      Figure 9. Regional age by system interaction for N1 latency within PMS.  
  
0
10
20
30
40
50
60
70
80
45 65 85 105 125 145 165 185 205
N
1
 L
at
en
cy
 (
m
s)
Age (months)
EGI
biosemi
64 
 
     Figure 10. Regional genotype by trial interaction for NN1 latency between PMS and controls. 
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      Figure 11. Deletion size by stimulus interaction for global N1 within PMS.  
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Appendix H: EEG Montage  
 
 
     Figure 12. BESA 33 Channel EEG Montage.  
